Roger Crystal
CIK 1656633 · Chief Executive Officer · last filed 2026-06-15
Roger Crystal is a Chief Executive Officer who has filed 24 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for DFTX, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$2.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $779.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OPNT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10TH FL.
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Director | 24,289 | $32.08 | $779.2K | $0 | 1 | 2026-06-15 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Director | 19,623 | $15.00 | $294.3K | $0 | 4 | 2025-06-16 |
| OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Chief Executive Officer | 6,667 | $20.65 | $137.7K | -$2.05M | 18 | 2023-03-03 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-15 | DFTX | Grant (A) | +4,666 | $0 | EDGAR |
| 2025-06-16 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-12 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-23 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | +13,671 | $0 | EDGAR |
| 2023-03-03 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Mixed | −80,439 | -$1.74M | EDGAR |
| 2023-01-31 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Sell (S) | −1,358 | -$27.5K | EDGAR |
| 2023-01-09 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Sell (S) | −1,183 | -$23.9K | EDGAR |
| 2023-01-05 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Sell (S) | −5,029 | -$101.6K | EDGAR |
| 2022-08-15 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | +89,286 | $0 | EDGAR |
| 2022-07-15 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Sell (S) | −2,246 | -$25.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).